AmCad BioMed Corporation (TPEX:4188)

AmCad BioMed Balance Sheet

Financials in millions TWD. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	15.99	24.6	17.76	29.66	47.04	58.51
Short-Term Investments	304.59	340.62	339.95	252.61	280.78	312.54
Trading Asset Securities	21.3	-	4	5	3.02	-
Cash & Short-Term Investments	341.88	365.22	361.71	287.27	330.84	371.05
Cash Growth	-12.99%	0.97%	25.91%	-13.17%	-10.84%	-6.09%
Accounts Receivable	5.22	9.34	20.66	11.35	4.51	5.78
Other Receivables	0	0.02	0.01	-	0.06	0.13
Receivables	5.22	9.37	20.66	11.35	4.57	5.91
Inventory	28.33	27.34	30.09	25.02	23.33	21.24
Prepaid Expenses	1.78	2.04	1.28	2.07	1.02	2.03
Other Current Assets	0.48	6.03	4.34	0.18	0.12	0.31
Total Current Assets	377.69	410	418.09	325.89	359.88	400.54
Property, Plant & Equipment	82.62	75.21	82.92	82.71	79.81	88.23
Long-Term Investments	98.3	75.8	125.68	28.06	28.74	34.47
Goodwill	31.18	31.18	31.18	31.18	31.18	31.18
Other Intangible Assets	25.75	28.77	35.15	42.5	50.54	58.62
Other Long-Term Assets	1.85	1.75	1.87	2.3	3.72	2.72
Total Assets	617.38	622.7	694.87	512.65	553.86	615.75

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	2.26	1.32	2.74	1.95	1.06	1.15
Accrued Expenses	7.23	-	-	-	-	-
Current Portion of Leases	4.76	1.31	5.15	4.4	3.88	4.42
Current Unearned Revenue	1.29	0.46	0.51	2.05	2.67	5.45
Other Current Liabilities	4.9	15.04	16.75	16.02	19.75	15.11
Total Current Liabilities	20.43	18.13	25.14	24.42	27.36	26.13
Long-Term Leases	8.59	3.44	5.72	9.99	6.43	10.31
Other Long-Term Liabilities	0.32	0.32	0.29	0.29	0.29	0.28
Total Liabilities	29.33	21.88	31.16	34.7	34.08	36.72

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	633.33	633.33	633.33	532.56	532.21	532.21
Additional Paid-In Capital	142.42	142.17	141.52	8.02	95.74	94.92
Retained Earnings	-281.71	-253.08	-199.32	-148.74	-192.06	-138.57
Comprehensive Income & Other	21.51	-0.99	-6.88	-11.25	-11.32	-5.59
Total Common Equity	515.55	521.42	568.65	380.58	424.58	482.98
Minority Interest	72.5	79.4	95.07	97.37	95.2	96.06
Shareholders' Equity	588.04	600.82	663.72	477.95	519.78	579.03
Total Liabilities & Equity	617.38	622.7	694.87	512.65	553.86	615.75

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	13.35	4.75	10.87	14.39	10.31	14.73
Net Cash (Debt)	328.54	360.47	350.84	272.88	320.53	356.32
Net Cash Growth	-14.83%	2.75%	28.57%	-14.87%	-10.04%	-8.84%
Net Cash Per Share	5.19	5.69	6.08	5.13	6.02	6.70
Filing Date Shares Outstanding	63.33	63.33	63.33	53.26	53.22	53.22
Total Common Shares Outstanding	63.33	63.33	63.33	53.26	53.22	53.22
Working Capital	357.26	391.87	392.94	301.47	332.52	374.41
Book Value Per Share	8.14	8.23	8.98	7.15	7.98	9.07
Tangible Book Value	458.62	461.48	502.33	306.9	342.87	393.18
Tangible Book Value Per Share	7.24	7.29	7.93	5.76	6.44	7.39
Land	52.94	52.94	52.94	52.94	52.94	52.94
Buildings	8.14	8.14	8.14	8.14	8.14	8.14
Machinery	16.74	14.99	15.57	25.15	48.47	47.34
Leasehold Improvements	-	-	-	-	0.82	0.82

Data Source: S&P Global Market Intelligence Last updated: Jun 30, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 24, 2026

Data Sources Report a data error